Key Takeaways
- Novo Nordisk intends to submit its oral Wegovy formulation to Chinese authorities in the coming months
- New CEO Mike Doustdar revealed the timeline during his inaugural China trip since assuming leadership last August
- Rival Eli Lilly already filed orforglipron with Chinese regulators in late 2025, securing a timing advantage
- China’s semaglutide patent lapsed in March, opening the door to generic manufacturers by the second quarter of 2026
- Shares of NVO gained 0.09% following the announcement, with analysts maintaining a Hold rating and $46 price target
Novo Nordisk is accelerating its entry into China’s burgeoning oral weight-loss medication sector, with Chief Executive Mike Doustdar revealing the pharmaceutical giant will seek regulatory clearance for its Wegovy pill formulation “very soon — a few months.”
Doustdar made this disclosure during his maiden visit to China following his appointment to the chief executive position in August of last year. At the time of the statement, NVO stock showed a modest uptick of 0.09%.
China represents the globe’s second-largest pharmaceutical marketplace, with GLP-1 weight-management drugs ranking among its most rapidly expanding therapeutic categories. According to investment firm Jefferies, first-quarter sales of GLP-1 medications through platforms like Alibaba and JD.com reached approximately 1.4 billion yuan (equivalent to $207 million).
The Danish drugmaker already maintains a presence in the market. Chinese authorities granted approval for its injectable Wegovy formulation in the middle of 2024. An oral alternative would provide the pharmaceutical company with an additional avenue, particularly appealing to patients who favor tablets over needle-based administration.
However, Novo finds itself trailing behind. Eli Lilly lodged its once-daily oral medication orforglipron with Chinese regulatory bodies in late 2025, positioning itself ahead in the approval timeline. Lilly has also established its Mounjaro brand in China for both Type 2 diabetes treatment and weight control.
Generic Competition Approaching Fast
The competitive landscape extends beyond Lilly. Semaglutide — the core compound in both Wegovy and Ozempic — saw its Chinese patent expire this past March. While Novo maintains regulatory data exclusivity through early next year, generic alternatives are anticipated to emerge as soon as the second quarter of 2026.
Doustdar recognized the competitive challenge but emphasized manufacturing complexity as a protective factor. “Not many of our competitors will be able to reach that level, have the capabilities,” he stated, highlighting the difficulties of producing the oral formulation at commercial scale.
In response to generic threats and domestic copycat products, Novo has already implemented price reductions for Wegovy in select Chinese regions.
Pfizer and domestic competitor Innovent Biologics have also entered the competitive arena, though precise market share data for China remains unclear. Neither Innovent nor Lilly publicly reports Chinese revenue breakdowns.
Novo introduced its oral Wegovy tablet in the United States earlier this year following expedited approvals in both the U.S. and United Kingdom markets. Lilly secured U.S. authorization for orforglipron in April.
Wall Street’s Perspective
Among Wall Street analysts, NVO stock receives a Hold consensus rating based on three unanimous Hold recommendations tracked by TipRanks. The mean price target stands at $46, suggesting approximately 4.7% potential upside from present trading levels.
Since the beginning of the year, NVO shares have declined 11.4%, mirroring investor concerns regarding patent vulnerabilities, pricing dynamics, and intensifying competition.
According to Doustdar, the Chinese regulatory submission is anticipated within the next several months.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
